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Abstract
Background: The histological discrimination of hyperplastic polyps from sessile serrated lesions can be difficult.
Sessile serrated lesions and hyperplastic polyps are types of serrated polyps which confer different malignancy risks,
and surveillance intervals, and are sometimes difficult to discriminate. Our aim was to reclassify previously
diagnosed hyperplastic polyps as sessile serrated lesions or confirmed hyperplastic polyps, using additional serial
sections.
Methods: Clinicopathological data for all colorectal hyperplastic polyps diagnosed in 2016 and 2017 was collected.
The slides were reviewed and classified as hyperplastic polyps, sessile serrated lesion, or other, using current World
Health Organization criteria. Eight additional serial sections were performed for the confirmed hyperplastic polyp
group and reviewed.
Results: Of an initial 147 hyperplastic polyps from 93 patients, 9 (6.1%) were classified as sessile serrated lesions,
103 as hyperplastic polyps, and 35 as other. Of the 103 confirmed hyperplastic polyps, 7 (6.8%) were proximal, and
8 (7.8%) had a largest fragment size of ≥5 mm and < 10 mm. After 8 additional serial sections, 11 (10.7%) were
reclassified as sessile serrated lesions. They were all less than 5 mm and represented 14.3% of proximal polyps and
10.4% of distal polyps. An average of 3.6 serial sections were required for a change in diagnosis.
Conclusion: Histopathological distinction between hyperplastic polyps and sessile serrated lesions remains a
challenge. This study has uncovered a potential role for the use of additional serial sections in the morphological
reappraisal of small hyperplastic polyps, especially when proximally located.
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Introduction
Although serrated polyps have in common a saw-tooth
morphology of crypts, it is important to distinguish be-
tween hyperplastic polyps (HPs) and sessile serrated le-
sions (SSLs) because of the inherent difference in risk of
malignant transformation [1]. This risk in turn informs
colonoscopic surveillance intervals [1–7].
Historically, colorectal polyps were classified as conven-
tional adenomas (adenomatous polyps) and hyperplastic
(metaplastic) polyps, with only the former being recog-
nised as having a risk of malignant transformation [2, 6, 8,
9]. In a landmark study published in 2003, Torlakovic
et al. proposed that not all hyperplastic polyps were equal,
and that there was a subgroup of serrated/ hyperplastic
polyps with morphological and genetic features distinct
from “benign” hyperplastic polyps, that were likely neo-
plastic [10, 11]. They proposed the use of the term “sessile
serrated adenoma” for these polyps [10]. The terms sessile
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serrated polyp, and sessile serrated adenoma/ polyp have
been used interchangeably [6, 12].
Serrated colonic neoplasia is now classified by the
World Health Organization (WHO) as; hyperplastic
polyps (HPs), sessile serrated lesions (SSLs) with or with-
out dysplasia, traditional serrated adenomas (TSAs), and
serrated adenoma, unclassified [2, 13]. Sessile serrated
lesions are more common in the right colon, and hyper-
plastic polyps in the left [13, 14]. International studies
show that HPs account for 83–96%, SSLs 3–11%, and
TSAs 1–7% of all serrated polyps [3]. However, there is
a paucity of data on the prevalence of sessile serrated le-
sions in the South African population.
Approximately 60% of colorectal carcinomas (CRCs)
are preceded by conventional adenomas via the classic
adenoma-carcinoma sequence, 5% are attributable to
Lynch syndrome, and serrated neoplasia accounts for
20–35% [3, 6, 9, 15–17]. There is strong evidence linking
SSLs and TSAs to CRC, whereas hyperplastic polyps are
generally considered to follow a benign course [2, 6, 8,
13, 18]. Serrated polyps can progress to CRC via the ser-
rated neoplasia pathway [2, 8, 16, 19–21]. They have also
been linked to interval carcinomas, especially proximally
[6, 16, 19, 21, 22]. Misinterpretation of SSLs as HPs may
contribute to this phenomenon.
There are a number of studies in which previously di-
agnosed hyperplastic polyps were reviewed and reclassi-
fied, in an attempt to improve diagnostic rates and
understanding of serrated neoplasia [4, 8, 23–25]. Many
of these have shown significant numbers being reclassi-
fied [14]. Interobserver variation in reclassification rates
has been attributed in part to the non-uniform applica-
tion of diagnostic criteria, and lack of awareness [21, 25].
Our search did not reveal similar published studies
based on African data. In addition, some authors have
advocated the routine use of additional/ deeper tissue
levels to aid in improving diagnosis of colorectal polyps,
whilst others have questioned their utility [13, 21, 26,
27]. As such there is no clear recommendation on how
many levels or sections are adequate to improve diagno-
sis of SSLs.
Materials and methods
Study design and setting
A retrospective review of HPs from the colorectum, di-
agnosed at Tygerberg Academic Hospital Division of
Anatomical Pathology, South Africa from 01/01/2016 to
31/12/2017 was conducted. Ethical approval was granted
by the Stellenbosch University Health Research Ethics
Committee.
Participants
A search of our pathology database was performed for
the period under review using SNOMED codes for
‘hyperplastic polyp’ and ‘colon’ or ‘rectum’. Demographic
and clinical data were extracted from electronic reports.
Suitable cases were selected using the following inclu-
sion criteria: HP diagnosis, adult patient (age ≥ 18 years),
original slides and wax blocks available, documented
polyp site, and no concurrent colorectal polyposis syn-
drome or colorectal carcinoma.
Simultaneous histological reviews of the original
haematoxylin and eosin (H&E) slides were conducted by
the two investigators (JR a senior pathologist with ex-
perience in gastrointestinal pathology, and DJ a senior
anatomical pathology resident). This culminated in a
consensus diagnosis of confirmed HP, SSL or other.
Eight additional serial sections were performed for the
confirmed HPs. Additional sections were placed in a
standard sequence on slides. On further review, a final
diagnosis of HP or SSL was rendered. The standard
practice in our laboratory is that multiple ‘upfront’ ser-
ial/ sequential sections are cut for each colorectal polyp
once the full face of the biopsy is seen. This number var-
ies according to the polyp size, generally ranging from 4
to 8. In this study serial sections and consecutive sec-
tions will be used interchangeably. During both stages of
histological review, the researchers were blinded to the
polyp site.
Diagnostic criteria
2019 WHO criteria for SSL were used [13]. The minimum
criterion was ‘the presence of at least one unequivocally
architecturally distorted crypt’ [13]. Features used to diag-
nose HPs included serrations limited to the surface epithe-
lium and superficial crypts, proliferative zones limited to
crypt bases, and evenly spaced crypts [13]. Basal dilatation,
significant distortion or submucosal misplacement should
have been absent [13]. See Fig. 1.
Data analysis
Clinicopathological variables analysed were: age, gender,
polyp site in relation to the splenic flexure (right- up to
and including, and left- distal to), and polyp size based
on the largest fragment (< 5 mm, 5–9mm and ≥ 10mm).
These variables were compared between confirmed HPs
and SSLs. The level at which the minimum diagnostic
criterion was first fulfilled on additional sections was
designated 1–8. Data collection and simple mathematical
analysis was performed using Microsoft Excel for Win-
dows. No statistical analysis was performed.
General pathologists as well as one pathologist with a
special interest in gastrointestinal pathology were re-
sponsible for reporting during the study period.
Results
The database search yielded 163 polyps from 150 pa-
tients, of which 147 polyps met the inclusion criteria.
Jaravaza and Rigby Diagnostic Pathology          (2020) 15:140 Page 2 of 9
The remainder were unsuitable due to wrong SNOMED
code, missing wax blocks, or missing original H&E
slides.
Initial review of the original slides resulted in reclassi-
fication of 9 (6.1%) of the HPs as SSLs. 55.6% of these
were distal, and 77.8% were < 5 mm. The remainder
were classified as confirmed HPs or other. The category
‘other’ comprised predominantly non-diagnostic normal
fragments of colorectal mucosa (37%), followed by in-
flammatory/ prolapse-type polyps (29%), and conven-
tional adenomas (29%). There were 2 misclassified
traditional serrated adenomas. See Figs. 2 and 3.
For 93 patients, contributing to the 103 confirmed
HPs, the mean and median ages were 59 and 62 years re-
spectively, with the youngest being 23 and the oldest 81
years. Fifty-eight polyps (56.3%) were from women, 96
(93.2%) were located distally, and the majority 95
(92.2%) were < 5 mm. None were ≥ 10 mm. See Table 1.
Of the 103 patients, 71 had one or more presenting
complaints or indications for colonoscopy documented.
The majority (75%) had one or more abdominal or lower
gastrointestinal tract symptoms. Haematochezia (27%)
was the most frequent of these, and anaemia the least
(1.4%). Additional indications included other symptom-
atology such as change in bowel habits or abdominal
pain, risk factors for colorectal carcinoma (32%) includ-
ing inflammatory bowel disease, previous colorectal
polyps or carcinoma, or a family history of colorectal
carcinoma. No cases were indicated as age-related
surveillance.
Further analysis of these confirmed HPs using eight
additional serial sections, resulted in reclassification of
11 (10.7%) as SSLs. All 11 were ≤ 5 mm. Although the
majority of these were distally located (90.9%), as a pro-
portion, 14.3% of proximal and 10.4% of distal HPs were
reclassified. When both site and size were considered, a
larger proportion of proximal polyps < 5mm (16.7%)
were reclassified as SSLs, compared to distal ones
(11.2%). A mean of 3.6 additional serial sections was re-
quired to reach a change in diagnosis. See Tables 1, 2
and 3. A change in diagnosis to SSL was made if at least
one of the diagnostic features was visualised on the add-
itional sections. The most common feature was horizon-
tal crypt growth, alone or in combination with other
features.
The mean age of patients with a final diagnosis of HP
was comparable to those whose polyps were reclassified as
SSLs (59 vs 60 years). However, patients with SSLs had a
narrower age range 45–76 compared to the wider age
range of patients with HPs (23–81 years). See Table 1.
Discussion
Colorectal cancer is the leading cause of cancer deaths
in the United States [8, 9]. According to the
Fig. 1 H&E stain. ×40 hyperplastic polyp (a), ×100 hyperplastic polyp showing superficial and crypt serration limited to the upper two-thirds (b),
× 100 sessile serrated polyp with boot- shaped crypt (c), × 100 traditional serrated adenoma with conspicuous eosinophilic cytoplasm, loss of
mucin, and pencillate nuclei (d)
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International Agency for Research on Cancer (IARC),
2020 report, the colorectum was the third most common
cancer site in men, and the second in women [28]. The
incidence rate in 2018 was higher in developed countries
(e.g. in Europe), compared to developing countries (e.g.
in Africa and Asia), at 20.9/100000 women in the
former, and 5.9/100000 women in the latter [28]. The
South Africa National Cancer Registry 2016 report indi-
cated that colorectal carcinoma was the 6th most com-
mon histologically diagnosed malignancy in women
(4.3%), and 4th most common in men (5.29%), which
translate to age-standardised incidence rates of 6.81/
100000 and 11.01/100000 respectively [29]. Breast car-
cinoma was the leading malignancy in women, and pros-
tate carcinoma in men.
Over a two-year period, only 163 colorectal polyps
were signed out as HPs. Similar studies showed sample
sizes ranging from 49 to 8324 [4, 11, 20, 24, 25]. The
lack of a National colonoscopic surveillance programme
in South Africa may account for this seemingly low
number. Abdominal and lower gastrointestinal tract
symptomatology was documented in 75% of patients,
whilst only 32% had recognised risk factors for colorectal
carcinoma.
Fig. 3 Flow diagram showing outcome of histological review of initial 163 cases
Fig. 2 H&E stain of HP reclassified as SSL. × 100 first (a) and fourth (b) of five sections of original slides showing features of hyperplastic polyp, ×
100 first of six additional sections showing hyperplastic polyp (c), third of additional sections showing hyperplastic polyp (d), fifth of additional
sections showing features of SSL at × 100 (e), and ×200 (f)






6.1% of the initial 147 polyps signed out as HPs were re-
classified as SSLs on the original slides using the current
WHO criteria, with only one displaying dysplastic fea-
tures. These cases most likely represent interobserver
variability which may be attributable in the greater part
to increasing knowledge and less strict criteria used cur-
rently than was applied during the review period. Using
the current criteria, at least one unequivocally architec-
turally distorted crypt was sought. During the study
period (2016–2017) the 2010 WHO criteria were more
stringent and required at least three affected crypts [30].
A number of authors had highlighted that these older
criteria were not clear-cut and the prerequisite of at least
three affected crypts might not be practical [31]. Prior to
the 2019 WHO edition, there was no uniformity as to
which criteria were used at our centre to diagnose SSLs,
with some opting for the less stringent Expert Panel rec-
ommendations, and others, the 2010 WHO [32].
23.8% of HPs were placed in the ‘other’ category which
included non-diagnostic, inflammatory/ prolapse type,
tubular adenoma, and TSAs. It is appreciated that pro-
lapse mucosal type changes can mimic HPs especially in
the left colon [25]. Confusion of HPs with tubular aden-
omas and TSAs is attributed to lack of awareness of
morphology.
Diagnostic criteria
The application of eight additional serial sections re-
sulted in reclassification of an additional 10.7% of HPs
as SSLs. None had dysplastic features. This reclassifica-
tion represents a higher proportion than when we ap-
plied the current WHO criteria alone (6.1%). Reported
rates of reclassification in the literature range from 2.6–
85%, in studies from 2007 to 2019 [4, 11, 19, 24, 25, 33–
40]. The wide range is mostly attributable to the mul-
tiple diagnostic criteria with different levels of stringency
that characterised earlier years [4, 7, 23, 31]. Of the
aforementioned studies, only Bettington et al., and Jan-
jua et al. relied solely on the WHO criteria (2010), whilst
Gill et al., and Khalid et al. used a combination of cri-
teria that included reference to the WHO [23–25, 37].
The remainder relied on those of Torlakovic et al.,
Snover et al., and local Pathology Societies [4, 11, 33–36,
38–40]. In a systematic review and meta-analysis in 2017
by Niv et al., a reclassification rate of 17% was reported,
which is comparable to this study [19]. Reported reclas-
sification rates of more than 30%, differed from the
current study in that they only assessed right sided HPs
(Gill et al), only polyps larger than 5mm (Tinmouth
et al), or did not utilise consensus criteria (Khalid et al)
[20, 25, 37]. Interestingly these three studies relied on a
combination of diagnostic criteria which included the
WHO. There were five studies reporting reclassification
rates lower than ours [33, 35, 38–40]. None of these uti-
lised the WHO criteria. Instead those of Snover et al.,
Torlakovic et al., the Expert Panel criteria, and the Ger-
man Society of Pathology were referenced. Of these, the
Expert Panel criteria were the least stringent, and closely
approximate the current WHO criteria. Although
Table 1 Clinicopathological characteristics of the study population
Age (years) Reclassified to SSL Remained HP
Mean 59 60 59
Median 62 63 62
Range 23–81 45–76 23–81
Initial HPs (n, %) Reclassified to SSL (n, %) Remained HP (n, %)
Total cases 103 (100) 11 (10.7) 92 (89.3)
Gender
Female 58 (56.3) 5 (45.5) 53 (57.6)
Male 45 (43.7) 6 (54.5) 39 (42.4)
Polyp site
Right 7 (6.8) 1 (9.1) 6 (6.5)
Left 96 (93.2) 10 (90.9) 86 (93.5)
Polyp size
< 5mm 95 (92.2) 11 (100) 84 (91.3)
5–9mm 8 (7.8) 0 8 (8.7)
≥ 10mm 0 0 0
Table 2 Diagnosis after performing eight additional sections
Cases % Right sided Left sided
Cases % Cases %
Sessile serrated lesion 11 10.7 1 14.3 10 10.4
Hyperplastic polyp 92 89.3 6 85.7 86 89.6
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current criteria are less stringent, it still appears that
SSLs remain underdiagnosed [5, 13, 23]. The application
of different diagnostic criteria is a well-recognised source
of interobserver variability [5, 23, 31, 41]. The strict, uni-
form application of consensus criteria however, im-
proves diagnostic reproducibility of SSLs [1, 42]. In
addition, diagnostic criteria specify only morphology as
integral to diagnosis [12].
Additional serial sections
6.1% of SSLs were diagnosed on the original H&E levels,
whilst 10.7% required an average of 3.6 additional serial sec-
tions over and above the ‘upfront’ ones. Many institutions
routinely request ‘upfront’ levels on all gastrointestinal bi-
opsies [26]. This requirement optimises the biopsy, espe-
cially when poorly orientated. Of the studies reviewed, only
two enumerated the number of tissue levels examined for
reclassification. Schachschal and colleagues analysed at least
8 serial sections of each polyp [39]. In a Swiss study on the
other hand, the standard was three levels. In a survey of
United Kingdom and North America based pathologists,
Chetty et al. reported that 86% of respondents had routine
levels processed for colorectal polyps, 7% reported the con-
verse and did not see the utility in requesting these to facili-
tate a diagnosis, and 7% used levels (routine or additional)
when considering the diagnosis of SSL [5]. Although War-
necke and colleagues specifically emphasise that deeper sec-
tions may be useful in differentiating serrated lesions,
especially HPs from SSLs, they did not find any significant
patient factors, endoscopic indications, or typical histo-
logical features that correlated with the yield of step sec-
tioning [43]. We could not find literature that specifically
evaluated the number of tissue levels in relation to reclassi-
fication of HPs. The general recommendation is that well
orientated specimens with visible crypt bases are essential
as the diagnosis of SSL relies on crypt architecture, and
may consist only of focal changes [13, 21, 40]. Thus, the
use of serial sections or step sections is advised, especially
in poorly orientated right sided polyps, equivocal, and pre-
dominantly superficial biopsies [12, 25, 44]. In five studies
investigating the utility of additional sectioning on diagnos-
tic yield of initially non- diagnostic colonic polyps, the yield
on additional sections ranged from 10 to 31.1%, with the
most common diagnosis being tubular adenomas and HPs
[43]. The study designs showed great disparity regarding
the number of routine sections (which involved serial sec-
tions, ribbons and step sections), or melting of wax blocks
and rotating of tissue. Additional tissue sections have at-
tendant labour, financial, turnaround time, storage, loss of
diagnostic tissue, and further ancillary testing implications,
which must be weighed against potential diagnostic yield
[26, 27, 45].
Polyp site
Proximal polyps accounted for only 6.8% of the 103
HPs, and 9.1% of reclassified SSLs. Three previous stud-
ies also reported SSLs being more numerous distally [24,
35, 40]. However, in one of these, SSLs were still more
likely to be proximally located than HPs [35]. 14.3% of
proximal polyps in this study were reclassified as SSLs,
in contrast to 10.4% of distal ones. This is consistent
with other reports [4, 20, 34, 35, 38]. In 111 patients
with polyps more than 5mm, Tinmouth et al. found that
28.8% of polyps were reclassified, comprising 48.5% of
proximal polyps and 17.3% of distal ones [20]. In a Win-
nipeg study, of 204 HPs, 11.8% were reclassified as SSLs,
comprising 17% of proximal versus 4% of distal polyps
[34]. Similarly, Farris et al. reported reclassifying 35% of
proximal and 18% of distal polyps [4]. Interestingly, Kim
et al. reported there being no right colon predilection
for SSLs misclassified as HPs [36]. The importance of
SSLs predominating in the proximal colon is that they
are susceptible to being missed at colonoscopy [17]. This
phenomenon is ascribed to their subtle endoscopic fea-
tures, a tendency to be obscured by mucus and debris,
and poorer bowel preparation proximally [8, 12, 16]. It is
notable that most interval carcinomas tend to be prox-
imal, and have been linked to preceding SSLs [3, 16, 19].
Some authors however, argue that interval carcinomas
are more likely to arise from missed or incompletely
resected lesions, than a specific molecular pathway [12].
Despite this proximal bias, proximal location should not
be regarded as a prerequisite for diagnosis [42]. From
this study, a lower threshold for serial sectioning could
be suggested for proximal hyperplastic-appearing polyps.
Polyp size
Polyp size is a recognised important clinical predictor of
subsequent dysplasia and invasive carcinoma [17, 42]. A
higher frequency of synchronous adenomas in patients
Table 3 Final diagnosis in relation to polyp site and size
Right sided (n = 7) Left sided (n = 96)
< 5mm 5–9mm < 5mm 5–9mm
Cases % Cases % Cases % Cases %
Sessile serrated lesion 1 16.7 0 0 10 11.2 0 0
Hyperplastic polyp 5 83.3 1 100 79 88.8 7 100
Total 6 100 1 100 89 100 7 100
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with large and (proximal) serrated polyps, has been re-
ported [6, 12]. In addition, large distal serrated polyps
are reported to be four times as likely to be associated
with a proximal adenocarcinoma [12]. Of the initial 147
HPs, 9 were reclassified as SSLs, without the perform-
ance of additional tissue levels. Only 2 were in the 5–9
mm range, and the rest were < 5mm. Of the 11 polyps
that were reclassified following additional serial sections,
all were < 5mm. This contrasts with most of the litera-
ture which emphasises larger size.
A meta-analysis of 2625 HPs from 8 studies, showed
that only proximal location and polyp size > 5mm was
statistically significant for an association with reclassifi-
cation as SSL [19]. In a study of 702 HPs, of the 188 that
were reclassified, 45.7% were < 5 mm, 44.2% 5–9mm,
and 10.1% ≥10 mm [4]. However, when comparing HP
polyps < 5 mm and those ≥5 mm, they found 20% of the
former and 37% of the latter were reclassified as SSLs.
They concluded that polyp size ≥5 mm was a predictor
of reclassification as an SSL (odds ratio, 2.09; 95% confi-
dence interval, 1.34–3.26) [4]. In a longitudinal study of
SSLs, high grade lesions were more likely to develop in
polyps > 5 mm, as compared to those ≤5 mm [35]. Tin-
mouth and colleagues reclassified only polyps > 5 mm,
and they found that 41.4% were 6–9 mm, and 58.6%,
≥10mm [20]. Some studies have disregarded polyps < 5
mm citing difficulty with orientation [11]. Others did
not find size to be a significant predictor of reclassifica-
tion [36, 38]. Pai et al. emphasise that diagnosis should
be primarily morphological, to enable adequate risk as-
sessment, for example with small proximal HPs [12].
The discrepancy in our study may be explained by
polyp size being measured as per the largest fragment
received in the laboratory. Bettington et al. are of the
opinion that this method is unreliable [23]. This is con-
troversial as others opine that using endoscopist dimen-
sions may be subjective [4]. In addition, inconsistent
documentation of endoscopic size, piecemeal resection,
biopsy instead of complete resection of larger polyps,
and fragmentation in transit, could also have contributed
to inaccuracies in size. Conversely, in relation to our
study, it may be that the difficulty with discrimination of
SSL from HP at our centre, is inversely related to polyp
size. The focal SSL changes in smaller polyps may re-
quire more diligent sectioning of the wax block to un-
cover them.
Age and gender
There was no difference between the mean age of pa-
tients whose polyps were reclassified to SSLs (60 years),
and those which remained HPs (59 years). However, the
age range for reclassification was narrower, with the pa-
tients middle aged and older (45–76 years) vs (23–81
years). Similarly, Bettington et al. found the mean age
for HP was 59.7 years and that for SSL was 58.6 years
[23]. The literature is divided regarding age. Some au-
thors did not find a significant relationship between re-
classification and age [19, 20, 23, 33, 36]. In contrast,
Schramm et al. found that age ≥ 65 years was signifi-
cantly associated with reclassification [38].
54.5% of our reclassified polyps occurred in men.
Schramm et al. reported an even higher frequency of SSLs
in men (82.9%) [38]. Two studies highlighted that SSLs
have a greater tendency to occur in women [22, 23]. How-
ever, the majority found that female gender was not a sig-
nificant predictor of reclassification [19, 20, 33, 36, 40].
Continental studies
Of the African studies reviewed, there is a low incidence
of serrated polyps in general, and SSLs in particular [46].
At one of South Africa’s tertiary institutions, it was re-
ported that 34% of patients with colorectal carcinoma
had synchronous colonic polyps [47]. Of these, the ma-
jority (51%) were tubular adenomas, whilst HPs (3%),
and sessile serrated adenomas (1%), were in the minority
[47]. A clinical review of colonoscopy findings of 989 pa-
tients conducted between January 2008 and March 2010,
in Johannesburg, South Africa revealed a majority 50.7%
were tubular adenomas, without any SSLs [48]. In con-
trast, a review of colonoscopy records conducted in
Cape Town, South Africa showed that of 246 polyps,
10.6% were hyperplastic and only 1.6% were serrated ad-
enomas. The latter were not further subclassified [49]. In
an Egyptian study, HPs accounted for 15% of non-
adenomatous polyps, the majority being hamartomatous.
No SSLs were reported [46]. A Nigerian study reported
30.8% inflammatory and hyperplastic polyps, but no
SSLs, in a clinicopathological review of patients present-
ing from 2013 to 2017 [50]. Whether the low reported
rates of SSLs on our continent are a true reflection of
our population, related to endoscopist polyp detection
rates, or a diagnostic dilemma, is uncertain.
Strengths, limitations, and applications
The strength of this study lies in that it was conducted
at a large, central referral hospital which is presumed
representative of the majority population who depend
on public health care. In addition, blinding to polyp lo-
cation during assessment helped to avoid bias when
assessing larger polyps. The single centre experience,
small sample size, unorientated, sometimes fragmented
specimens, submission of multiple biopsies in the same
container, and lack of an expert gastrointestinal path-
ology consult service may have posed limitations.
There are application possibilities arising from this
study such as using findings to inform the development
of quality assessment tools for the optimum orientation,
processing, and interpretation of colonoscopic biopsy
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specimens, in collaboration with the Gastroenterology
department. They can also be used as a platform to dis-
cuss discrepant diagnoses of tubular adenomas and
TSAs with pathologists. Other centres could conduct
similar reviews to improve understanding of the preva-
lence of SSLs in their populations, and increasing diag-
nostic accuracy through familiarisation with, and
uniform application of current WHO criteria.
In some Western populations the diagnosis of some
SSLs informs a shorter colonoscopic surveillance interval
[3, 19, 22]. The progression rate for SSLs is thought to
be slower than that of adenomatous polyps [21]. An out-
come of hyperplastic polyps reclassified as SSLs should
translate to a shorter follow-up interval, as our institu-
tion follows the 2012 US Multi-Society Task Force on
Colorectal Cancer Guidelines. As the reclassified SSLs
were small, no change to clinical management was insti-
tuted for these cases. When National colonoscopic sur-
veillance guidelines become available in our country, it
is envisaged that improved diagnosis of SSLs will posi-
tively impact colorectal carcinoma prevention.
Conclusion
The histopathological discrimination of HPs from SSLs
can be difficult. This study has uncovered a potential
role for the use of additional serial sections over and
above ‘upfront’ levels, especially for proximal hyperplas-
tic polyps less than 5 mm in size. In addition, familiarity
with, and consistent application of current WHO diag-
nostic criteria for SSLs is imperative. Due to the small
sample size of this study, additional research is recom-
mended. Improved diagnostic accuracy will prevent un-
necessary, expensive investigations on one hand, and
interval colorectal carcinoma on the other hand.
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